bioAffinity Technologies, Inc. splits its revenue into 6 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Health Care Patient Service at $1.2 million, 82% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6
|
2
|
1
|
2
|
1
|
1
|
2
|
2
|
2
|
| Health Care Patient Service |
5
-26.1%
share 81.1%
|
1
+32.1%
share 82.4%
|
1
-31.1%
share 80.1%
|
1
-32.9%
share 80.7%
|
1
-42.8%
share 81.1%
|
1
share 74.2%
|
2
share 84.7%
|
2
share 86.8%
|
2
share 87.2%
|
| Histology Service Fees |
1
-9.0%
share 17.7%
|
0
-19.6%
share 16.4%
|
0
-5.0%
share 18.5%
|
0
-1.0%
share 18.1%
|
0
-9.3%
share 17.7%
|
0
share 24.3%
|
0
share 14.2%
|
0
share 13.2%
|
0
share 12.0%
|
| Medical Director Fees |
0
+3.1%
share 1.2%
|
0
+1.4%
share 1.2%
|
0
+5.3%
share 1.3%
|
0
+4.0%
share 1.1%
|
0
+2.0%
share 1.2%
|
0
share 1.4%
|
0
share 0.9%
|
0
share 0.7%
|
0
share 0.7%
|
| Department Of Defense Observational Studies |
—
|
—
|
0
share 0.1%
|
—
|
—
|
—
|
—
|
—
|
0
share 0.1%
|
| Diagnostic Research And Development |
—
|
—
|
0
share 0.1%
|
—
|
—
|
—
|
—
|
—
|
0
share 0.1%
|
| Other Revenues |
0
+110.9%
share 0.0%
|
0
-57.9%
share 0.0%
|
—
|
0
+101.4%
share 0.0%
|
0
share 0.0%
|
0
share 0.1%
|
0
share 0.2%
|
-0
share -0.7%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.